High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pediatric population

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3350-3356

  Antonov, Nina K ^a   Garzon, Maria C ^b   Morel, Kimberly D ^b   Whittier, Susan ^b   Planet, Paul J ^b,c   Lauren, Christine T ^b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^c DIVISION OF INVERTEBRATE ZOOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSEUDOMONIC ACID; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; ATOPIC DERMATITIS; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; EPIDERMOLYSIS BULLOSA; FEMALE; HUMAN; IMMUNE DEFICIENCY; INFANT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RESIDENTIAL AREA; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; UNITED STATES; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PRESCHOOL CHILD; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MUPIROCIN; PREVALENCE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; YOUNG ADULT;

EID: 84929648668     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00079-15     Document Type: Article

References (38)

1. Coia JE, Duckworth GJ, Edwards DI, Farrington M, Fry C, Humphreys H, Mallaghan C, Tucker DR, Joint Working Party of the British Society of Antimicrobial Chemotherapy, Hospital Infection Society, Infection Control Nurses Association. 2006. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 63(Suppl 1):S1-S44. http://dx.doi.org/10.1016/j.jhin.2006.01.001.
2. Rahman M, Noble WC, Cookson B. 1987. Mupirocin-resistant Staphylococcusaureus. Lancet ii:387-388.
3. Kavi J, Andrews JM, Wise R, Smith MD, Sanghrajka M, Lock S. 1987. Mupirocin-resistant Staphylococcus aureus. Lancet ii:1472-1473.
4. Hodgson JE, Curnock SP, Dyke KG, Morris R, Sylvester DR, Gross MS. 1994. Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870. Antimicrob Agents Chemother 38:1205-1208. http://dx.doi.org/10.1128/AAC.38.5.1205.
5. Seah C, Alexander DC, Louie L, Simor A, Low DE, Longtin J, Melano RG. 2012. MupB, a new high-level mupirocin resistance mechanism in Staphylococcus aureus. Antimicrob Agents Chemother 56:1916-1920. http://dx.doi.org/10.1128/AAC.05325-11.
6. Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA. 2003. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect Control Hosp Epidemiol 24:342-346. http://dx.doi.org/10.1086/502218.
7. Fritz SA, Hogan PG, Camins BC, Ainsworth AJ, Patrick C, Martin MS, Krauss MJ, Rodriguez M, Burnham CA. 2013. Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections. Antimicrob Agents Chemother 57:559-568. http://dx.doi.org/10.1128/AAC.01633-12.
8. Antonio M, McFerran N, Pallen MJ. 2002. Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 46:438-442. http://dx.doi.org/10.1128/AAC.46.2.438-442.2002.
9. Hetem DJ, Bonten MJ. 2013. Clinical relevance of mupirocin resistance in Staphylococcus aureus. J Hosp Infect 85:249-256. http://dx.doi.org/10.1016/j.jhin.2013.09.006.
10. Simor AE, Stuart TL, Louie L, Watt C, Ofner-Agostini M, Gravel D, Mulvey M, Loeb M, McGeer A, Bryce E, Matlow A, Canadian Nosocomial Infection Surveillance Program. 2007. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 51:3880-3886. http://dx.doi.org/10.1128/AAC.00846-07.
11. Rossney A, O'Connell S. 2008. Emerging high-level mupirocin resistance among MRSA isolates in Ireland. Euro Surveill 13:8084.
12. Desroches M, Potier J, Laurent F, Bourrel AS, Doucet-Populaire F, Decousser JW, Microbs Study Group. 2013. Prevalence of mupirocin resistance among invasive coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus (MRSA) in France: emergence of a mupirocin-resistant MRSA clone harbouring mupA. J Antimicrob Chemother 68:1714-1717. http://dx.doi.org/10.1093/jac/dkt085.
13. Perez-Roth E, Lopez-Aguilar C, Alcoba-Florez J, Mendez-Alvarez S. 2006. High-level mupirocin resistance within methicillin-resistant Staphylococcus aureus pandemic lineages. Antimicrob Agents Chemother 50: 3207-3211. http://dx.doi.org/10.1128/AAC.00059-06.
14. Sareyyupoglu B, Ozyurt M, Haznedaroglu T, Ardic N. 2008. Detection of methicillin and mupirocin resistance in staphylococcal hospital isolates with a touchdown multiplex polymerase chain reaction. Folia Microbiol (Praha) 53:363-367. http://dx.doi.org/10.1007/s12223-008-0056-4.
15. Hogue JS, Buttke P, Braun LE, Fairchok MP. 2010. Mupirocin resistance related to increasing mupirocin use in clinical isolates of methicillin-resistant Staphylococcus aureus in a pediatric population. J Clin Microbiol 48:2599-2600. http://dx.doi.org/10.1128/JCM.02118-09.
16. McNeil JC, Hulten KG, Kaplan SL, Mason EO. 2011. Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children. Antimicrob Agents Chemother 55:2431-2433. http://dx.doi.org/10.1128/AAC.01587-10.
17. McNeil JC, Hulten KG, Kaplan SL, Mason EO. 2014. Decreased susceptibilities to Retapamulin, Mupirocin, and Chlorhexidine among Staphylococcus aureus isolates causing skin and soft tissue infections in otherwise healthy children. Antimicrob Agents Chemother 58:2878-2883. http://dx.doi.org/10.1128/AAC.02707-13.
18. Lee AS, Macedo-Vinas M, François P, Renzi G, Vernaz N, Schrenzel J, Pittet D, Harbarth S. 2011. Trends in mupirocin resistance in meticillinresistant Staphylococcus aureus and mupirocin consumption at a tertiary care hospital. J Hosp Infect 77:360-362. http://dx.doi.org/10.1016/j.jhin.2010.11.002.
19. Talon D, Marion C, Thouverez M, Bertrand X. 2011. Mupirocin resistance is not an inevitable consequence of mupirocin use. J Hosp Infect 79:366-367. http://dx.doi.org/10.1016/j.jhin.2011.08.009.
20. Caffrey AR, Quilliam BJ, LaPlante KL. 2010. Risk factors associated with mupirocin resistance in meticillin-resistant Staphylococcus aureus. J Hosp Infect 76:206-210. http://dx.doi.org/10.1016/j.jhin.2010.06.023.
21. Cadilla A, David MZ, Daum RS, Boyle-Vavra S. 2011. Association of high-level mupirocin resistance and multidrug-resistant methicillinresistant Staphylococcus aureus at an academic center in the midwestern United States. J Clin Microbiol 49:95-100. http://dx.doi.org/10.1128/JCM.00759-10.
22. Park SY, Kim SM, Park SD. 2012. The prevalence, genotype and antimicrobial susceptibility of high- and low-level mupirocin resistant methicillin-resistant Staphylococcus aureus. Ann Dermatol 24:32-38. http://dx.doi.org/10.5021/ad.2012.24.1.32.
23. Uhlemann AC, Dordel J, Knox JR, Raven KE, Parkhill J, Holden MT, Peacock SJ, Lowy FD. 2014. Molecular tracing of the emergence, diversification, and transmission of S. aureus sequence type 8 in a New York community. Proc Natl Acad Sci U S A 111:6738-6743. http://dx.doi.org/10.1073/pnas.1401006111.
24. Suh L, Coffin S, Leckerman KH, Gelfand JM, Honig PJ, Yan AC. 2008. Methicillin-resistant Staphylococcus aureus colonization in children with atopic dermatitis. Pediatr Dermatol 25:528-534. http://dx.doi.org/10.1111/j.1525-1470.2008.00768.x.
25. Matiz C, Tom WL, Eichenfield LF, Pong A, Friedlander SF. 2011. Children with atopic dermatitis appear less likely to be infected with community acquired methicillin-resistant Staphylococcus aureus: the San Diego experience. Pediatr Dermatol 28:6-11. http://dx.doi.org/10.1111/j.1525-1470.2010.01293.x.
26. Perkins D, Hogue JS, Fairchok M, Braun L, Viscount HB. 2008. Mupirocin resistance screening of methicillin-resistant Staphylococcus aureus isolates at Madigan Army Medical Center. Mil Med 173:604-608. http://dx.doi.org/10.7205/MILMED.173.6.604.
27. Chaves F, Garcia-Martinez J, de Miguel S, Otero JR. 2004. Molecular characterization of resistance to mupirocin in methicillin-susceptible and -resistant isolates of Staphylococcus aureus from nasal samples. J Clin Microbiol 42:822-824. http://dx.doi.org/10.1128/JCM.42.2.822-824.2004.
28. Rotger M, Trampuz A, Piper KE, Steckelberg JM, Patel R. 2005. Phenotypic and genotypic mupirocin resistance among staphylococci causing prosthetic joint infection. J Clin Microbiol 43:4266-4268. http://dx.doi.org/10.1128/JCM.43.8.4266-4268.2005.
29. Limbago B, Fosheim GE, Schoonover V, Crane CE, Nadle J, Petit S, Heltzel D, Ray SM, Harrison LH, Lynfield R, Dumyati G, Townes JM, Schaffner W, Mu Y, Fridkin SK, Active Bacterial Core Surveillance Investigators MRSA. 2009. Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: a population-based analysis. J Clin Microbiol 47: 1344-1351. http://dx.doi.org/10.1128/JCM.02264-08.
30. Knox J, Uhlemann AC, Miller M, Hafer C, Vasquez G, Vavagiakis P, Shi Q, Lowy FD. 2012. Environmental contamination as a risk factor for intra-household Staphylococcus aureus transmission. PLoS One 7:e49900. http://dx.doi.org/10.1371/journal.pone.0049900.
31. Biedenbach DJ, Bouchillon SK, Johnson SA, Hoban DJ, Hackel M. 2014. Susceptibility of Staphylococcus aureus to topical agents in the United States: a sentinel study. Clin Ther 36:953-960. http://dx.doi.org/10.1016/j.clinthera.2014.04.003.
32. Moy JA, Caldwell-Brown D, Lin AN, Pappa KA, Carter DM. 1990. Mupirocin-resistant Staphylococcus aureus after long-term treatment of patients with epidermolysis bullosa. J Am Acad Dermatol 22:893-895. http://dx.doi.org/10.1016/0190-9622(90)70120-7.
33. van der Kooi-Pol MM, Veenstra-Kyuchukova YK, Duipmans JC, Pluister GN, Schouls LM, de Neeling AJ, Grundmann H, Jonkman MF, van Dijl JM. 2012. High genetic diversity of Staphylococcus aureus strains colonizing patients with epidermolysis bullosa. Exp Dermatol 21:463-466. http://dx.doi.org/10.1111/j.1600-0625.2012.01502.x.
34. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD, Comparative Sequence Program NISC, Murray PR, Turner ML, Segre JA. 2012. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 22:850- 859. http://dx.doi.org/10.1101/gr.131029.111.
35. Jinnestål CL, Belfrage E, Bäck O, Schmidtchen A, Sonesson A. 2014. Skin barrier impairment correlates with cutaneous Staphylococcus aureus colonization and sensitization to skin-associated microbial antigens in adult patients with atopic dermatitis. Int J Dermatol 53:27-33. http://dx.doi.org/10.1111/ijd.12198.
36. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak JM, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285-292. http://dx.doi.org/10.1093/cid/cir034.
37. Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, Twombley J, French PP, Herwaldt LA, Mupirocin and the Risk Of Staphylococcus Aureus Study Team. 2002. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 346: 1871-1877. http://dx.doi.org/10.1056/NEJMoa003069.
38. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, Lankiewicz J, Gombosev A, Terpstra L, Hartford F, Hayden MK, Jernigan JA, Weinstein RA, Fraser VJ, Haffenreffer K, Cui E, Kaganov RE, Lolans K, Perlin JB, Platt R, CDC Prevention Epicenters Program, AHRQ DECIDE Network and Healthcare-Associated Infections Program. 2013. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 368: 2255-2265. http://dx.doi.org/10.1056/NEJMoa1207290.